Four months after restructuring the ailing Aegerion and axing about 80 staffers, CEO Mary Szela has completed the deal she wanted to bring in a late-stage asset.
Aegerion announced this morning that it will merge with Vancouver-based QLT, creating a new biotech named Novelion that leaves the QLT shareholders with the lion’s share of the stock and Szela with the helm.
An investment syndicate led by Deerfield is also stepping in to inject $22 million into the company through a share purchase agreement. And QLT’s investors will wind up with 67% of the shares of Novelion.
Shares of Aegerion shot up 42% on Wednesday morning.
Aegerion was afflicted by a variety of troubles. Ex-CEO Marc Beer ran into a hornet’s nest of regulatory issues, accused of making unsubstantiated claims about its drug Juxtapid. The drug, meanwhile, fell far short of expectations on the market, and Beer’s messy divorce added a few salacious allegations that helped set the stage for activist investor Alex Denner to push for a change.
That change became Szela, who had left Melinta earlier.
“A late-stage agent would be particularly impactful,” Szela told me earlier in the year as she sought to right a listing ship.
That asset materialized in QLT’s zuretinol (QLT091001) which the companies describe as a Phase III-ready orphan drug targeting inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes, spotlighting Leber Congenital Amaurosis and Retinitis Pigmentosa.
QLT, meanwhile, has experienced its own turmoil. The Canadian biotech has announced and called off two earlier mergers, including a recent pact with Auxilium.
Now Szela will see if she can make one good biotech out of two troubled companies, with its HQ in Canada and its operations in Cambridge, MA. It’s a sizable task.
By John Carroll
Source: Fierce Biotech
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.
